Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
ALLISON GATLIN

TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?

TG Therapeutics shares soared Wednesday after sales of the company's new multiple sclerosis treatment met expectations. TGTX stock bounded off its 200-day line.

The drug, known as Briumvi, generated $39.9 million in U.S. sales. That was in line with the company's preannouncement for $40 million in sales.

On today's stock market, TGTX stock rocketed 26.7% to 17.63. Shares bounced off their 200-day moving average and hit their highest point since Jan. 10, the day TG Therapeutics unveiled its preliminary look at fourth-quarter sales. On that day, however, shares collapsed 15.4%, MarketSmith.com shows.

TG Therapeutics: An Easier MS Treatment

TG Therapeutics is marketing Briumvi as an easier option for multiple sclerosis treatment. After initially receiving two loading doses, patients switch to Briumvi's maintenance schedule. That requires a one-hour infusion every six months. Other MS drugs require more frequent infusions.

But on Wednesday, TG reiterated its outlook for $220 million to $260 million in U.S. sales of Briumvi. That missed expectations in January. TGTX stock analysts currently forecast $262.6 million in global sales this year. That includes license, milestone and other sources of revenue.

Is The Biotech Rally Buoying TGTX Stock?

Overall, the biotech segment is experiencing something of a resurgence. The move by TGTX stock is likely part of that. On Tuesday, the SPDR S&P Biotech exchange traded fund closed above 100 for the first time in two years. That was helped by triple-digit moves for Viking Therapeutics and Janux Therapeutics.

On Wednesday, the XBI fund pulled back 1.3%. Numerous stocks notched double-digit gains, led by vTv Therapeutics. That gain was due to a $51 million private placement in vTv shares.

TGTX stock was the second biggest biotech gainer — not including dollar and penny stocks — ahead of Editas Medicine. The latter also issued its fourth-quarter report, though it doesn't yet have a commercial product available.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.